Treg-enriched donor cells

This experimental cell therapy approach, developed by the Dana-Farber Cancer Institute, is designed for patients with relapsed/refractory or ultra-high-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The therapy is part of an immunosuppression-free (IS-free) haploidentical hematopoietic cell transplantation (HCT) protocol. It involves the infusion of donor-derived regulatory T cells (Tregs) that have been enriched to suppress graft-versus-host disease (GVHD). This is followed by the infusion of unmodified donor T cells, which provide a graft-versus-leukemia (GVL) effect, and CD34+ peripheral blood stem cells to rescue hematopoiesis. By using Tregs to control alloreactivity, the protocol aims to eliminate the need for traditional post-transplant immunosuppressive medications while maximizing the anti-tumor activity of the donor's immune system.

Other names

IS-free Treg-cell graft-engineered haplo transplanthaplo Treg-enriched donor cellsregulatory T cell-enriched donor cells